Regarding molecular subtypes, 14 patients (41.2 %) had hormone receptor (HR)-positive/HER2-negative tumors, eight (23.5 %) had HR-positive/HER2-positive tumors, four (11.8 %) had HER2-enriched tumors, and eight (23.5 %) had triple-negative breast cancer (TNBC). The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.